A failure at Eli Lilly, the comeback drug teplizumab shows off more upbeat diabetes data in the run-up to an FDA filing
Provention Bio has some more positive data to add to its looming BLA for a new treatment designed to delay the onset of diabetes among patients.
Their new trial data for teplizumab boosted the average amount of time it takes for a patient to be diagnosed with type 1 diabetes to 5 years, adding a year to their earlier number compared to a steady 2 years for the placebo arm.
Researchers added that they are tracking clear evidence that the drug can stabilize and then reverse deteriorating C-peptide levels, “suggesting a delay in the destruction of beta cells and restoration of insulin production by dysfunctional beta cells. Importantly, even in those who advanced to clinical-stage T1D, treatment with teplizumab resulted in a slower decline in C-peptide levels compared to placebo.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.